Appointment

June 25, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Appointment of Mr. Anil Kumar Matai as an Independent Director Dear Sir/ Madam, With reference to captioned subject and pursuant to Regulation 30 (read with Part A of Schedule III) of the SEBI LODR Regulations, we would like to inform you that, on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its Meeting held today, inter-alia, considered and approved, appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an additional director in the category of Non-Executive Independent Director of the Company w.e.f. 25th June, 2026. The term of his appointment as an Independent Director will be for a period of 5 (Five) years and the appointment is subject to the approval of shareholders of the Company. The details required under Regulation 30 of the Listing Regulations read with applicable SEBI Circular(s) in respect of appointment of Directors, are enclosed herewith as Annexure-I. We hereby affirm that Mr. Anil Kumar Matai is not debarred or disqualified from being appointed as Director of the Company by SEBI/Ministry of Corporate Affairs or such other statutory authority. The Board Meeting commenced at 4:45 p.m. and concluded at 05:30 p.m. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance office Annexure-I Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule Ill of the Listing Regulations read with SEBI master circular HO/49/14/14(7)2025-CFD- POD2/l/3762/2026 dated January 30, 2026 related to appointment as mentioned below: S. Particulars Description 1. Reason for Change viz appointment, re-appointment, Appointment of Mr. Anil Kumar Matai (DIN: resignation, removal, death or otherwise; 03122685) as an Additional Director in the category of Non-Executive Independent Director 2. Date of appointment/cessation & w.e.f June 25, 2026, for a period of 5 (Five) years and term of appointment his appointment shall be subject to the approval of shareholders 3. Brief Profile Anil Matai is a seasoned life sciences leader with over 35 years of experience across multinational corporations, Indian pharma companies, and private equity. He is currently serving as the Director General of OPPI (Organisation of Pharmaceutical Producers of India), where he drives healthcare policy, innovation, and industry sustainability. Over his career, he has held senior leadership roles including CEO of Novartis India Ltd., President & MD of Zydus Healthcare Ltd., and Operating Partner at Jashvik Capital. His journey spans diverse industries such as pharmaceuticals, healthcare, consumer sectors, and manufacturing, with a proven track record in scaling businesses, integrating organizations, and shaping strategic growth. 4. Disclosure of relationships between Directors (In There is no inter-se relations between Mr. Anil case of appointment of Director) Kumar Matai and the others members of Board.